selective SMARCA4 degrader / Dr. Reddy’s, Aurigene - LARVOL DELTA

Selective degradation of SMARCA4 as a therapeutic strategy in SMARCA4 driven cancers (AACR 2026) - "These findings establish proof-of-concept for targeting SMARCA4 via targeted protein degradation as a novel strategy for treating SMARCA4-driven cancers with improved safety margin. Advanced in-vivo studies are in progress to complete candidate nomination by Q1 2026"

Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • PTEN • SMARCA2 • SMARCA4

Identification of first-in-class paralog selective SMARCA4 degraders for treatment of hematological and prostate malignancies (AACR 2025) - "Identified compounds have shown selective degradation of SMARCA4 over SMARCA2 in multiple cell lines. Few potent SMARCA4 selective degraders were optimized for pharmacokinetic properties and further evaluation of tolerability and efficacy in rodents is in progress."

Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • PTEN • SMARCA2 • SMARCA4